DYADIC INTERNATIONAL Business Summary

Dyadic International Inc. (rebranded as Dyadic Applied BioSolutions) is a biotechnology company that generates revenue through a mix of technology licensing, R&D collaborations, milestone payments, and the direct commercial sale of ancillary recombinant proteins. The company operates across three primary segments: Life Sciences, focusing on cell culture media and molecular biology reagents; Food & Nutrition, providing non-animal enzymes and proteins; and Bioindustrial, targeting the cellulosic enzyme market. By leveraging its proprietary C1 fungal-based gene expression platform, Dyadic offers a high-yield, cost-effective alternative to traditional mammalian (CHO) and yeast production systems. Its direct competitors include Repare Therapeutics, Immunic, and Novonesis; Dyadic distinguishes itself as a specialized provider of high-titer, non-therapeutic input proteins that bypass the regulatory complexity of clinical-grade biologics. Founded by Mark A. Emalfarb, who has served as CEO since 1979 and holds over 25 patents, the leadership team is anchored by President and COO Joe Hazelton, a former Novartis executive appointed in 2025 to spearhead the company's commercial pivot. Financial oversight is managed by CFO Ping Wang Rawson, while Dr. Ronen Tchelet leads technical innovation as VP of Research and Business Development. The Board of Directors is chaired by Patrick Lucy, a co-founder of Pfenex Inc. with extensive experience in protein expression platforms. Notable institutional backing includes Apis Capital Advisors and Bandera Partners, reflecting a seasoned governance structure that includes long-standing independent directors such as Dr. Seth Herbst and Jack Kaye.